UNSPSC 51282421: Piperacillin anhydrous

This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C23H27N5O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I628532GX, chemically known as piperacillin, anhydrous, but more generally known as piperacillin anhydrous, which bears US NIH Compound Identifier 43672. European Medicines Agency schedules piperacillin anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09867MIG.

Most nations, for tariff purposes, schedule piperacillin anhydrous under HS 29411090. Piperacillin anhydrous bears US NLM identifiers UMLS ID C1882383 and NCI Concept Code C61891. SMILES: CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2CCCCC2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O.

UNSPSC 51282421 Piperacillin anhydrous is a Commodity code for a specific pharmaceutical active ingredient; however, the recent state and local opportunities tagged under this code do not reflect procurement of piperacillin anhydrous itself. Instead, the tagged solicitations address finished pharmaceutical products and medical supplies—specifically antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) and naloxone with drug deactivation systems. This mismatch suggests the code may be misapplied in state and local procurement systems, or the tagging reflects a broader pharmaceutical-supply classification practice that does not align with the UNSPSC commodity specificity. State and local buyers using this code appear to be departments of health and county health authorities procuring finished pharmaceutical inventory through piggyback contracts and competitive bid processes to support public health initiatives, emergency preparedness, and community health programs.

Recent activity includes the Illinois Department of Public Health's award to Chartwell Rx LLC on August 28, 2026, for a piggyback pharmaceutical warehouse contract totaling $2,999,999.11 over three years (an IFB process), and Seminole County, Florida's IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023 (note: this opportunity's response date appears historically dated relative to the posting date, suggesting a data-entry issue in the source). The Illinois opportunity leveraged the MMCAP Infuse consortium purchasing vehicle, while the Seminole County procurement required quarterly deliveries and E-Verify compliance. Geographic spread across recent activity includes Illinois and Florida. No other states or jurisdictions appear in the available records.